Cost-effectiveness of rosuvastatin for cardiovascular prevention in high-risk populations in Sweden

被引：0
|
作者：
Jonsson, L.
Ekman, M.
Karlsson, G.
Brun, J.
机构：
[1] European Hlth Econ, London, England
[2] Stockholm Hlth Econ, Stockholm, Sweden
[3] AstraZeneca, Sodertalje, Sweden
来源：
VALUE IN HEALTH | 2006年 / 9卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)63646-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A346 / A346
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF ENVIRONMENTAL SURVEILLANCE IN A HIGH-RISK NEONATAL UNIT
    ELDER, D
    RICHARDSON, H
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 1977, 68 (04): : 338 - 339
  • [32] Cost-Effectiveness of Treatment Strategies for High-Risk Prostate Cancer
    Kowalchuk, R. O.
    Breen, W.
    Harmsen, W. S.
    Jeans, E.
    Morris, L. K.
    Mullikin, T. C.
    Miller, R. C.
    Wong, W. W.
    Vargas, C. E.
    Trifiletti, D. M.
    Phillips, R.
    Choo, C. R.
    Davis, B. J.
    Pisansky, T. M.
    Tendulkar, R. D.
    Stish, B. J.
    Waddle, M. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E342 - E342
  • [33] COST-EFFECTIVENESS OF TICLOPIDINE IN PREVENTING STROKE IN HIGH-RISK PATIENTS
    OSTER, G
    HUSE, DM
    LACEY, MJ
    EPSTEIN, AM
    STROKE, 1994, 25 (06) : 1149 - 1156
  • [34] COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN
    Lindgren, P.
    Hagstrom, E.
    van Hout, B.
    Villa, G.
    Pemberton-Ross, P.
    Arellano, J.
    Sibartie, M.
    Fonarow, G. C.
    VALUE IN HEALTH, 2019, 22 : S548 - S548
  • [35] Cost-Effectiveness of Rosuvastatin for Primary Prevention of Cardiovascular Events According to Framingham Risk Score in Patients With Elevated C-Reactive Protein
    MacDonald, Gary P.
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2010, 110 (08): : 427 - 436
  • [36] COST-EFFECTIVENESS ANALYSIS OF AN ADJUSTED POLYGENIC RISK SCORE IN CARDIOVASCULAR DISEASE PREVENTION
    Hatziandreou, E.
    Panagiotou, N.
    VALUE IN HEALTH, 2023, 26 (12) : S81 - S81
  • [37] Anastrozole for the prevention of breast cancer in high-risk postmenopausal women: cost-effectiveness analysis in the UK and the USA
    XiaoXia Wei
    Jiaqin Cai
    Huiting Lin
    Wenhua Wu
    Jie Zhuang
    Hong Sun
    BMC Health Services Research, 24
  • [38] Primary prevention of variceal hemorrhage in high-risk patients: A cost-effectiveness analysis incorporating patient compliance
    Park, BJ
    Shehab, TM
    Inadomi, JM
    GASTROENTEROLOGY, 2001, 120 (05) : A375 - A375
  • [39] COST-EFFECTIVENESS OF PRIMARY AND SECONDARY PREVENTION OF FATAL PULMONARY-EMBOLISM IN HIGH-RISK SURGICAL PATIENTS
    HULL, RD
    HIRSH, J
    SACKETT, DL
    STODDART, GL
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1982, 127 (10) : 990 - &
  • [40] Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients
    Balogh, Julius
    Burroughs, Sherilyn Gordon
    Boktour, Maha
    Patel, Samir
    Saharia, Ashish
    Ochoa, Robert A.
    McFadden, Robert
    Victor, David W.
    Ankoma-Sey, Victor
    Galati, Joseph
    Monsour, Howard P., Jr.
    Fainstein, Victor
    Li, Xian C.
    Grimes, Kevin A.
    Gaber, A. Osama
    Aloia, Thomas
    Ghobrial, R. Mark
    LIVER TRANSPLANTATION, 2016, 22 (02) : 163 - 170
12345